Skip to main content
logo
Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
28.46
+0.50 (1.79%)
At close: Aug 31, 2026, 4:00 PM EDT
28.51
+0.05 (0.18%)
After-hours: Aug 31, 2026, 7:59 PM EDT

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020Q3 2020
Period Ending
Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Oct '23 Jul '23 Apr '23 Dec '22 Oct '22 Jul '22 Apr '22 Dec '21 Oct '21 Jul '21 Apr '21 Dec '20 Sep '20
Primary Care Revenue
5.50B
Oncology Revenue
4.17B
Specialty Care Revenue
3.35B
Hospital and Biosimilars Revenue
1.64B
Global Pharmaceuticals Business (Biopharma) Revenue
14.66B
Business Innovation (Pfizer CentreOne) Revenue
373.00M
Revenue (Other)
-
Revenue (Total)
15.03B

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020Q3 2020
Period Ending
Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Oct '23 Jul '23 Apr '23 Dec '22 Oct '22 Jul '22 Apr '22 Dec '21 Oct '21 Jul '21 Apr '21 Dec '20 Sep '20
United States Revenue
8.86B
Developed Markets Revenue
3.74B
Emerging Markets Revenue
2.43B
Revenue (Other)
-
Revenue (Total)
15.03B

Revenue by Geography 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020Q3 2020
Period Ending
Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Oct '23 Jul '23 Apr '23 Dec '22 Oct '22 Jul '22 Apr '22 Dec '21 Oct '21 Jul '21 Apr '21 Dec '20 Sep '20
United States Revenue
8.86B
Revenue (Total)
15.03B

Revenue by Geography 3

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020Q3 2020
Period Ending
Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Oct '23 Jul '23 Apr '23 Dec '22 Oct '22 Jul '22 Apr '22 Dec '21 Oct '21 Jul '21 Apr '21 Dec '20 Sep '20
United States Revenue
8.86B
International Revenue
6.18B
Revenue (Total)
15.03B

EBT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020Q3 2020
Period Ending
Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Oct '23 Jul '23 Apr '23 Dec '22 Oct '22 Jul '22 Apr '22 Dec '21 Oct '21 Jul '21 Apr '21 Dec '20 Sep '20
Global Pharmaceuticals Business (Biopharma) Earnings
6.89B
Other Business Activities Earnings
-1.71B

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020Q3 2020
Period Ending
Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Oct '23 Jul '23 Apr '23 Dec '22 Oct '22 Jul '22 Apr '22 Dec '21 Oct '21 Jul '21 Apr '21 Dec '20 Sep '20
Comirnaty - Direct Sales and Alliance Revenue
261.00M
Eliquis - Direct Sales and Alliance Revenue
2.43B
Paxlovid Revenue
21.00M
Prevnar Family Revenue
1.34B
Nurtec ODT/Vydura Revenue
421.00M
Abrysvo Revenue
208.00M
Vyndaqel Family Revenue
1.76B
Xeljanz Revenue
251.00M
Ibrance Revenue
1.06B